| Literature DB >> 31402871 |
Yuan Quan1,2,3, Fengji Liang1, Yuexing Zhu2, Ying Chen2, Zi Xu2, Fang Du2, Ke Lv1, Hailong Chen1, Lina Qu1, Ruifeng Xu3, Hong-Yu Zhang4, Jianghui Xiong1,2, Yinghui Li1,2.
Abstract
Numerous studies have shown that changes in the epigenome are an important cause of human biochemical or metabolic parameter changes. Biochemical/metabolic parameter disorders of the human body are usually closely related to the occurrence of disease. Therefore, constructing credible DNA methylation site-biochemical/metabolic parameter associations are key in interpreting the pathogenesis of diseases. However, there is a lack of research on systematic integration analysis of DNA methylation with biochemical/metabolic parameter and diseases. In this study, we attempted to use the four-people, multiple time point detected data from the long-term isolation experiment to conduct a correlation analysis. We used the biclustering algorithm FABIA to cluster the DNA methylation site-parameter correlation matrixes into 28 biclusters. The results of the biological function analysis for these biclusters were consistent with the biochemical/metabolic parameter change characteristics of the human body during long-term isolation, demonstrating the reliability of the biclusters identified by our method. In addition, from these biclusters, we obtained highly credible biochemical/metabolic parameter-disease associations, which is supported by several studies. Our results indicate that there is an overlap of biochemical/metabolic parameter-disease associations derived from a small sample, multiple time point data in healthy populations and the associations obtained from a large sample data in patients during disease development. These findings provide insights into understanding the role of the epigenome in biochemical/metabolic parameter change and disease development and has potential applications in biology and medicine research.Entities:
Keywords: DNA methylation; biochemical/metabolic parameters; diseases; long-term isolation environment; multiple time point detected data
Year: 2019 PMID: 31402871 PMCID: PMC6676193 DOI: 10.3389/fphys.2019.00917
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
The summary of sd(β).
| Min. | 0.0005088 | 0.0003659 | 0.0005051 | 0.0005218 |
| 1st Qu. | 0.0064724 | 0.0064956 | 0.0066463 | 0.0066737 |
| Median. | 0.0128403 | 0.0131087 | 0.0128721 | 0.0128599 |
| Mean. | 0.0161165 | 0.0160469 | 0.0157420 | 0.0157409 |
| 3rd Qu. | 0.0213100 | 0.0217733 | 0.0210371 | 0.0211823 |
| Max. | 0.3461165 | 0.3629779 | 0.3497298 | 0.2542050 |
The summary of err(β).
| Min. | 0.000000 | 0.000000 | 0.000000 | 0.000000 |
| 1st Qu. | 0.001800 | 0.001775 | 0.002006 | 0.002214 |
| Median. | 0.004839 | 0.004745 | 0.005488 | 0.006678 |
| Mean. | 0.008024 | 0.007923 | 0.009936 | 0.012305 |
| 3rd Qu. | 0.010925 | 0.010556 | 0.012715 | 0.016583 |
| Max. | 0.392298 | 0.384768 | 0.450809 | 0.359334 |
FIGURE 1Infinium HumanMethylation450 BeadChip data preprocessing.
FIGURE 2FABIA results for DNA methylation-biochemical/metabolic parameter correlation matrixes. (A) For volunteer A, (B) for volunteer B, (C) for volunteer C, (D) for volunteer D.
FIGURE 3The Venn diagram of DNA methylation probes or genes contained in seven biclusters of different volunteers. (A) for DNA methylation probes, (B) for DNA methylation genes.
FIGURE 4The gene positional distribution of DNA methylation probes for the original 450k chip, FABIA input probes, and FABIA-derived biclusters of the four volunteers.
FIGURE 5The biochemical/metabolic parameters covering more than 13 FABIA-derived biclusters (bicluster number ≥ 13).
FIGURE 6KEGG pathway enrichment analysis for FABIA-derived biclusters of the four volunteers (bicluster number ≥ 4).
FIGURE 7Enrichment analysis of KEGG pathway catalogs for FABIA-derived biclusters of the four volunteers.
Enriched diseases of the FABIA-derived biclusters (covering ≥ 20 biclusters).
| Cardiovascular diseases | Telangiectasis | 24 |
| Vascular diseases | 24 | |
| Ataxia telangiectasia | 21 | |
| Angina, unstable | 20 | |
| Chemical induced disorders | Alcoholism | 28 |
| Substance-related disorders | 28 | |
| Tobacco use disorder | 28 | |
| Nervous system diseases | Cataplexy | 24 |
| Narcolepsy | 24 | |
| Restless legs syndrome | 24 | |
| Sleep disorders | 24 | |
| Sleep initiation and maintenance disorders | 23 | |
| Nutritional and Metabolic Diseases | Metabolic diseases | 20 |
FIGURE 8The Venn diagram of DNA methylation probe/gene-biochemical/metabolic parameter associations of different volunteers. (A) For DNA methylation probes, (B) for DNA methylation genes.
FIGURE 9Validation of DNA methylation gene-biochemical/metabolic parameter associations using the STITCH database. (A) By the hypergeometric test, (B) by the permutation test. Lines indicate the frequency of STITCH-validated associations derived from 1,000 random combinations of DNA methylation genes and biochemical/metabolic parameters, and red triangle indicate the number of STITCH-validated associations obtained from the FABIA-derived biclusters.
The most significant biochemical/metabolic parameter-disease associations (top 20).
| Formic acid | Atrial fibrillation | 1.56e-06 | |
| Methylbutyrylglycine | Anemia, aplastic | 1.71e-06 | |
| Formic acid | Arrhythmias, cardiac | 5.15e-06 | |
| VA (vitamin a) | Sarcopenia | 1.01e-05 | |
| Cortisol | Carcinoma, renal cell | 1.58e-05 | |
| Methylbutyrylglycine | Myelodysplastic syndromes | 1.75e-05 | |
| Methylbutyrylglycine | Polycythemia vera | 1.76e-05 | |
| VA (vitamin a) | Muscle spasticity | 2.09e-05 | |
| FFA (free fatty acid) | Pain | 2.67e-05 | |
| TG (triglyceride) | Atrial fibrillation | 3.49e-05 | |
| VEGF (vascular endothelial growth factor) | Malabsorption syndromes | 4.60e-05 | |
| Methylnicotinamide | Memory disorders | 4.80e-05 | |
| Acetylaminooctanoic acid | Impulse control disorders | 4.95e-05 | |
| Quercetin | Thrombocytopenia | 5.10e-05 | |
| Methylbutyrylglycine | Hematologic neoplasms | 5.17e-05 | |
| Aspartylaspartic acid | Carcinoma, neuroendocrine | 6.47e-05 | |
| GGT (gamma-glutamyltransferase) | Carcinoma, neuroendocrine | 6.47e-05 | |
| Acetylaminooctanoic acid | Adrenoleukodystrophy | 6.98e-05 | |
| TG (triglyceride) | Arrhythmias, cardiac | 7.23e-05 | |
| Methylbutyrylglycine | Anemia | 7.70e-05 |